Deoxynivalenol Hepatotoxicity: Interplay Between Mitophagy and Nrf2 Pathway Disruption

Study Background and Research Question

Deoxynivalenol (DON), a trichothecene mycotoxin produced by Fusarium fungi, is a widespread contaminant in cereals and animal feeds worldwide. Its chemical stability and resistance to standard food processing mean that DON exposure remains a persistent threat to human and animal health. Epidemiological data show high detection rates in both feed and food—up to 97% in some regions—raising substantial concerns about its chronic toxicity. The liver, as the primary organ responsible for xenobiotic metabolism, accumulates DON at the highest concentrations following exposure, yet the precise molecular mechanisms underlying DON-induced hepatotoxicity have remained incompletely defined (reference study).

While prior research links DON exposure to mitochondrial dysfunction and oxidative stress in hepatic tissues, the dual involvement of mitophagy and antioxidant defense pathways has not been fully delineated. This study aimed to resolve how DON orchestrates these intracellular processes to drive liver injury, focusing on the balance between PINK1/Parkin-mediated mitophagy and the p62-Keap1-Nrf2 signaling axis.

Key Innovation from the Reference Study

The central innovation of the reference study lies in its mechanistic dissection of DON-induced liver injury, specifically demonstrating that DON simultaneously:

• Overactivates PINK1/Parkin-mediated mitophagy, resulting in excessive removal of mitochondria and subsequent mitochondrial dysfunction.
• Suppresses the p62-Keap1-Nrf2 pathway, thereby compromising the cell's antioxidant defense and exacerbating hepatocellular damage.

Importantly, the study offers direct evidence that restoring the p62-Keap1-Nrf2 axis—such as by p62 overexpression—mitigates DON-induced injury, highlighting a potentially actionable node for intervention.

Methods and Experimental Design Insights

The researchers employed both in vivo and in vitro approaches. C57BL/6 mice were administered DON at doses ranging from 0 to 4.8 mg/kg over seven days to model subacute liver injury, while AML-12 hepatocyte cells were exposed to DON concentrations of 0 to 6.4 μM for 24 hours. These dual systems allowed for interrogation of both systemic and cellular effects.

Key experimental manipulations included:

• Pharmacological inhibition of mitophagy using Mdivi-1, a selective Drp1 inhibitor, to assess the role of excessive mitophagy in DON toxicity.
• Genetic silencing of PINK1 via siRNA to further probe the necessity of the PINK1/Parkin pathway in DON-induced mitochondrial injury.
• Overexpression of p62 to test whether reactivation of the antioxidant pathway could reverse or attenuate liver damage.

Readouts included histopathological liver assessment, quantification of apoptosis, oxidative stress markers, inflammation, and lipid metabolism disturbances. The activity of the Nrf2 pathway was monitored by evaluating nuclear translocation of Nrf2 and downstream antioxidant enzyme expression.

Protocol Parameters

• DON administration in mice: 0–4.8 mg/kg body weight, daily for 7 days, to induce subacute liver injury.
• AML-12 cell exposure: 0–6.4 μM DON for 24 hours, modeling acute cellular toxicity.
• Mitophagy inhibition: Mdivi-1 used at protocol-defined doses prior to DON exposure to block excessive mitophagy.
• PINK1 silencing: siRNA transfection 24 hours before DON treatment to reduce PINK1-dependent mitophagy.
• p62 overexpression: Transfection with p62 expression vector to enhance Nrf2 signaling and test cytoprotection.

Core Findings and Why They Matter

The study provides compelling evidence that DON exposure leads to a pathological overactivation of PINK1/Parkin-mediated mitophagy, which, rather than protecting hepatocytes, results in excessive mitochondrial loss and cell damage. This process triggers a cascade of apoptosis, oxidative stress, inflammatory signaling, and lipid metabolic disturbances in the liver. Notably, these effects are exacerbated by a simultaneous suppression of the p62-Keap1-Nrf2 pathway, the cell’s principal cytoprotective response to oxidative stress (reference study).

Crucially, interventions that either block mitophagy or restore p62/Nrf2 signaling (via p62 overexpression) were able to substantially reduce liver damage, supporting the model that the intersection of these pathways is central to DON’s hepatotoxic mechanism. These mechanistic insights suggest that future strategies for protecting against DON toxicity should target both mitochondrial quality control and antioxidant defense systems.

Comparison with Existing Internal Articles

Internal reviews of DON-induced liver injury, such as the summary "Deoxynivalenol Liver Injury: Mitophagy and Nrf2 Pathway Disruption", corroborate the central finding that DON’s hepatotoxicity is mediated by dual modulation of mitophagy and the Nrf2 axis. These resources emphasize the translational importance of understanding these molecular mechanisms for experimental model design.

In translational oncology and toxicology, the Wnt5a-induced ROR1 signaling pathway has emerged as another axis implicated in cellular stress responses and tumor progression. Internal articles such as "Anti-ROR1 Antibody (Zilovertamab): New Horizons in Translational Oncology" and "Anti-ROR1 Antibody (Zilovertamab): Applied Workflows & Troubleshooting" discuss how targeting ROR1 and its downstream signaling can intersect with models of liver injury and cancer, particularly when using robust anti-tumor antibodies or functional assay antibodies in in vitro and in vivo systems. These cross-domain insights offer an expanded experimental toolkit for researchers studying related mechanisms of cellular injury and repair.

Limitations and Transferability

While the study’s findings significantly advance our understanding of DON hepatotoxicity, several limitations warrant consideration. First, as with many preclinical studies, the translation of findings from mouse and cell models to human biology requires careful validation. The use of pharmacological inhibitors and genetic manipulation (siRNA, overexpression) may not fully recapitulate chronic human exposure scenarios or the complexity of in vivo regulatory networks. The study also does not address long-term adaptation or compensation mechanisms that might emerge with prolonged DON exposure.

Moreover, although evidence links mitophagy and antioxidant pathways to liver injury, potential interactions with other stress signaling cascades—such as Wnt5a-induced ROR1 signaling—are not directly explored in the reference study. Nonetheless, internal resources suggest that integrating insights from both mitophagy/Nrf2 and ROR1 pathway research could enhance the fidelity of experimental liver injury models and inform therapeutic target selection.

Research Support Resources

For laboratories aiming to explore the molecular mechanisms described above, high-specificity reagents are essential. The Anti-ROR1 Antibody (Zilovertamab) (SKU F1460) is a humanized monoclonal antibody targeting ROR1, validated for use in ELISA, FACS, kinetic studies, functional assays, and animal models. It enables precise inhibition of Wnt5a-induced ROR1 signaling, which is increasingly recognized in both cancer and toxicology research. According to the product information, Zilovertamab’s high purity and specificity make it suitable for translational studies that demand reproducible antibody performance in complex biological systems. APExBIO provides detailed protocols to support integration into diverse research workflows.